FPAS
TNYA icon

Focus Partners Advisor Solutions’s Tenaya Therapeutics TNYA Stock Holding History

Focus Partners Advisor Solutions’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,464
Closed -$7.01K – 1283
2025
Q2 		$7.01K Buy
+11,464
New +$5.83K ﹤0.01% 1096

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Focus Partners Advisor Solutions's TNYA Position: Q3 2025 in Review

Focus Partners Advisor Solutions sold out of Tenaya Therapeutics (TNYA) in Q3 2025, closing a stake of 11,464 shares — an estimated $7.01K sold.

Focus Partners Advisor Solutions first reported a position in TNYA in Q2 2025 and held it in 1 quarter. The position peaked at $7.01K in Q2 2025. 91 funds tracked by Wall St. Rank hold TNYA as of Q3 2025.

  • Focus Partners Advisor Solutions reported no remaining Tenaya Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Focus Partners Advisor Solutions sold 11,464 Tenaya Therapeutics shares in Q3 2025, an estimated $7.01K.
  • Focus Partners Advisor Solutions first reported a position in Tenaya Therapeutics in Q2 2025 and held it in 1 quarter.
  • Focus Partners Advisor Solutions's Tenaya Therapeutics position peaked at $7.01K in Q2 2025.
  • 91 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2025.

Based on Focus Partners Advisor Solutions's 13F filing for Q3 2025, filed 12 Nov 2025.